Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX004497-01A2 |
| Title: | CCN5 Therapy for Triple Negative Breast Cancer |
| Principal Investigator: | Sushanta K. Banerjee |
| Location: | Kansas City, MO |
| Congressional District Code: | 5 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | October 2019 - September 2023 |
| FY 2021 Funding Amount: | $329,302 |
| Total Award Amount (all years): |
$1,540,986 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Current therapies for breast cancer (BC) are firmly believed to improve patient survival efficiently. However, one-third of aggressive triple-negative breast cancer (TNBC) patients may relapse more frequently compared to hormone receptor-positive subtypes, and patients may eventually develop the distant metastatic disease and drug resistance. There are no targeted therapies currently available for invasive and metastatic diseases, indicating a dire need for improved therapy. We revealed that CCN... |